| donepezil / Generic mfg. |
NCT01406145: A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil |
|
|
| Completed | 1b | 60 | US | ASP0777, Placebo | Astellas Pharma Inc | Alzheimer's Disease | 11/11 | 11/11 | | |
NCT01181310: Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED) |
|
|
| Completed | 1 | 31 | Europe | A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine, B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg, C: MK-3134 25 mg + Scopolamine 0.5 mg, D: Donepezil 10 mg + Scopolamine 0.5 mg, Aricept (donepezil), E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg | Merck Sharp & Dohme LLC | Dementia | 10/07 | 10/07 | | |
NCT00713765: Pharmacokinetic Interaction Between AZD3480 and Donepezil |
|
|
| Terminated | 1 | 33 | Europe | AZD3480, Donepezil | AstraZeneca | Alzheimer's Disease | 12/08 | 12/08 | | |
NCT00874939: A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023) |
|
|
| Terminated | 1 | 4 | NA | MK-0249 7.5 mg, MK-0249 25 mg, Donepezil 5mg, Aricept, Placebo to MK-0249, Placebo to Donepezil | Merck Sharp & Dohme LLC | Alzheimer's Disease, Dementia | 04/09 | 04/09 | | |
NCT00777608 / 2008-003377-41: A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED) |
|
|
| Completed | 1 | 106 | Europe | Comparator: Placebo 5mg (run in), Donepezil 5 - 10 mg, Comparator: Placebo 5-10 mg, Donepezil 10 mg | Merck Sharp & Dohme LLC | Alzheimer's Disease | 10/09 | 04/10 | | |
NCT01042314: Drug-Drug Interaction Study With Aricept® (Donepezil) |
|
|
| Completed | 1 | 18 | US | Donepezil, Aricept®, BMS-708163 | Bristol-Myers Squibb | Alzheimer Disease | 04/10 | 04/10 | | |
|
NCT01028911: A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease |
|
|
| Terminated | 1 | 9 | US | PF-03654746, Placebo | Pfizer | Alzheimer's Disease | 05/10 | 05/10 | | |
NCT01024660: The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil |
|
|
| Completed | 1 | 155 | Canada, Europe, RoW | Donepezil, Aricept, Placebo to match Aricept | AstraZeneca | Alzheimer's Disease | 01/11 | 01/11 | | |
| Completed | 1 | 15 | Europe | Galantamine and Donepezil | University Hospital, Clermont-Ferrand, Janssen-Cilag Farmaceutica Ltda. | Alzheimer's Disease | 09/13 | 09/13 | | |
NCT01903824: Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects |
|
|
| Completed | 1 | 40 | Europe | CEP-26401, Irdabisant, donepezil hydrochloride, Aricept, modafinil, Provigil, Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Cognitive Impairment | 10/13 | 12/13 | | |
NCT02051335: Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults |
|
|
| Completed | 1 | 27 | Europe | Roflumilast, Daxas, Roflumilast placebo, Donepezil, Aricept, Donepezil placebo, Scopolamine, Hyoscine hydrobromide | AstraZeneca | Memory Impairment, Alzheimer's Disease | 05/14 | 05/14 | | |
